Russell Frank Company’s Ligand Pharmaceuticals LGND Stock Holding History

Russell Frank Company’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$50.6M	Buy	757,235 +86,420	+13%	+$5.25M	0.09%	249
2015 Q4	$45.3M	Buy	670,815 +75,403	+13%	+$4.66M	0.08%	275
2015 Q3	$31.8M	Buy	595,412 +72,010	+14%	+$4.37M	0.06%	362
2015 Q2	$32.9M	Sell	523,402 -73,890	-12%	-$4.03M	0.05%	405
2015 Q1	$28.7M	Buy	597,292 +54,107	+10%	+$2.07M	0.05%	409
2014 Q4	$17.7M	Buy	543,185 +38,947	+8%	+$1.27M	0.03%	622
2014 Q3	$14.8M	Buy	504,238 +152,163	+43%	+$5.05M	0.03%	696
2014 Q2	$10.8M	Buy	352,075 +51,009	+17%	+$2.07M	0.02%	870
2014 Q1	$12.6M	Buy	301,066 +25,143	+9%	+$1.05M	0.02%	754
2013 Q4	$10.4M	Buy	275,923 +172,974	+168%	+$5.64M	0.02%	838
2013 Q3	$2.78M	Sell	102,949 -16,040	-13%	-$451K	﹤0.01%	1682
2013 Q2	$2.78M	Buy	+118,989	New	+$2.14M	0.01%	1581

Other funds holding LGND

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Russell Frank Company's LGND Position: Q1 2016 in Review

Russell Frank Company increased its Ligand Pharmaceuticals (LGND) stake by 13% in Q1 2016, buying an estimated $5.25M and bringing the position to 757,235 shares worth $50.6M. The position accounts for 0.09% of the portfolio, ranked #249.

Russell Frank Company first reported a position in LGND in Q2 2013 and has held it in 12 quarters since. 251 funds tracked by Wall St. Rank hold LGND as of Q1 2016.

Russell Frank Company held 757,235 shares of Ligand Pharmaceuticals worth $50.6M as of Q1 2016.
Russell Frank Company bought 86,420 Ligand Pharmaceuticals shares in Q1 2016, an estimated $5.25M.
Ligand Pharmaceuticals made up 0.09% of Russell Frank Company's portfolio in Q1 2016, its #249 holding.
Russell Frank Company first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
251 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.